- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: 3003-005 | Darzalex® | HuMax-CD38 | JNJ-54767414
daratumumab is an approved drug (FDA (2015), EMA (2017))
Compound class: Antibody
Comment: Daratumumab is a monoclonal antibody directed against CD38.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Daratumumab is reported to induce complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) in patient-derived multiple myeloma cells .
Peptide sequence analysis of the heavy chain variable region of daratumumab matches a sequence claimed in patent US7829673 , and is the heavy chain component of monoclonal −005 described therein. Daratumumab does not cross‐react with rodent CD38 or cynomolgus monkey CD38 .
|Selectivity at other protein targets|
|Key to terms and symbols||Click column headers to sort|